MCET Stock Overview

A biopharmaceutical company, develops novel therapeutics and discovery tools for the treatment of neurological disorders, hepatic disease, cancer, and interventional cardiology and peripheral vessel applications. More details

MCET fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Latest financial reports are more than a year old

Does not have a meaningful market cap ($5K)

My Notes

Capture your thoughts, links and company narrative

MultiCell Technologies, Inc. Competitors

Genocea Biosciences

OTCPK:GNCA.Q

US$5.9k

Innovation Pharmaceuticals

OTCPK:IPIX

US$52.9k

Molecular Templates

OTCPK:MTEM

US$208.7k

Histogen

OTCPK:HSTO.Q

US$118.1k

Price History & Performance

Summary of share price highs, lows and changes for MultiCell Technologies
Historical stock prices
Current Share Price	US$0.000001
52 Week High	US$0.0005
52 Week Low	US$0.000001
Beta	0
1 Month Change	0%
3 Month Change	0%
1 Year Change	n/a
3 Year Change	-99.00%
5 Year Change	-99.00%
Change since IPO	-100.00%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	MCET	US Biotechs	US Market
7D	0%	1.9%	0.7%
1Y	n/a	-6.6%	23.9%

Return vs Industry: Insufficient data to determine how MCET performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how MCET performed against the US Market.

Price Volatility

Is MCET's price volatile compared to industry and market?
MCET volatility
MCET Average Weekly Movement	n/a
Biotechs Industry Average Movement	11.0%
Market Average Movement	6.4%
10% most volatile stocks in US Market	18.7%
10% least volatile stocks in US Market	3.1%

Stable Share Price: Data is not available.

Volatility Over Time: Insufficient data to determine MCET's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1962	n/a	Jerry Newmin	n/a

MultiCell Technologies, Inc., a biopharmaceutical company, develops novel therapeutics and discovery tools for the treatment of neurological disorders, hepatic disease, cancer, and interventional cardiology and peripheral vessel applications. Its product portfolio comprises MCT-125, a Phase II therapeutic candidate for the treatment of primary multiple sclerosis-related fatigue; MCT-465, a preclinical synthetic double-stranded RNA (dsRNA) therapeutic candidate and potent immune enhancer for the treatment of solid tumor cancers; and MCT-485, a discovery stage dsRNA therapeutic candidate with tumor cytolytic properties for the treatment of various cancers. The company also develops Ideal BioStent, a bioabsorbable stent for interventional cardiology and peripheral vessel applications.

MultiCell Technologies, Inc. Fundamentals Summary

How do MultiCell Technologies's earnings and revenue compare to its market cap?
MCET fundamental statistics
Market cap	US$5.00k
Earnings (TTM)	-US$253.60k
Revenue (TTM)	US$805.24k

0.0x

P/S Ratio

0.0x

P/E Ratio

Is MCET overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
MCET income statement (TTM)
Revenue	US$805.24k
Cost of Revenue	US$216.92k
Gross Profit	US$588.31k
Other Expenses	US$841.92k
Earnings	-US$253.60k

Last Reported Earnings

Aug 31, 2015

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did MCET perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/01/08 02:13
End of Day Share Price	2024/12/31 00:00
Earnings	2015/08/31
Annual Earnings	2014/11/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

MultiCell Technologies, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution